350 руб
Журнал «Вопросы биологической, медицинской и фармацевтической химии» №5 за 2011 г.
Статья в номере:
Рецепторы мелатонина и их агонисты
Ключевые слова: мелатонин мелатониновые рецепторы и сайты связывания агонисты мелатониновых рецепторов
Авторы:
Н.В. Костюк - к.б.н., доцент, ст. преподаватель, кафедра биологической и органической химии, Тверская государственная медицинская академия (ТГМА). E-mail: p001637@mail.ru В.В. Жигулина - к.б.н., ст. преподаватель, кафедра биологической и органической химии, ТГМА. E-mail: jerlan-1991-2006@list.ru М.Б. Белякова - к.б.н., ст. преподаватель, кафедра биологической и органической химии, ТГМА. E-mail: mayabe@yandex.ru Д.В. Лещенко - к.б.н., доцент, кафедра биологической и органической химии, ТГМА. E-mail: dvleshchenko@mail.ru М.В. Миняев - к.б.н., науч. сотрудник лаборатории научно-исследовательского центра, ТГМА. E-mail: mmb_77@mail.ru
Аннотация:
В организме млекопитающих эпифизарный гормон мелатонин выступает в роли регулятора сезонных и суточных циклов, влияет на деятельность сердечно-сосудистой и иммунной системы, ограничивает процессы пролиферации клеток. В реализации клеточного ответа принимают участие многочисленные рецепторы и сайты связывания (МТ1, МТ2, МТ3, GPR50, RZR/ROR, RZR/ROR). Хотя достигнуты определенные успехи в использовании мелатонина в терапии различных заболеваний, более широкое внедрение препарата в медицинскую практику ограничено из-за его быстрого метаболизма организме. В последние годы синтезирован ряд новых мелатонинергических агонистов - потенциальных лекарственных средств. В данном обзоре представлена современная информация, касающаяся структуры и функций мелатониновых рецепторов, поиска их специфических агонистов.
Страницы: 49-59
Список источников
  1. Zawilska J.B., Skene D.J., Arendt J. Physiology and pharmacology of melatonin in relation to biological rhythms // Pharm. Reports. 2009. V. 61. № 3. P. 383-410.
  2. Арушанян Э.Б. Гормон эпифиза мелатонин и его лечебные возможности // Российский медицинский журнал. 2005. Т. 13. № 26. С. 1755-1760.
  3. Анисимов В.Н. Мелатонин. Роль в организме, применение в клинике. СПб: Система. 2007.
  4. Кветная Т.В., Князькин И.В., Кветной И.М. Мелатонин - нейроиммуноэндокринный маркер возрастной патологии. СПб: ДЕАН, 2005.
  5. Hardeland R., Poeggeler B., Srinivasan V. et al. Melatonergic drugs in clinical practice // Arzneimittelforschung. 2008. V. 58. № 1. P. 1-10.
  6. Klein D.C. Arylalkylamine N-acetyltransferase: "the Timezyme" // J. Biol. Chem. 2007. V. 282. P. 4233-4237.
  7. Falcon J., Besseau L., Fuentes M. et al. Structural and functional evolution of the pineal melatonin system in vertebrates // Ann. N.Y. Acad. Sci. 2009. V. 1163. P. 101111.
  8. Hardeland R. Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites // Cell. Mol. Life. Sci. 2008. V. 65. № 13. P. 2001-2018.
  9. Герман С.В. Мелатонин у человека // Клиническая медицина. 1993. Т. 71. № 3. С. 22-30.
  10. Арушанян Э.Б., Арушанян Л.Г. Модуляторные свойства эпифизарного мелатонина // Пробл. эндокринол. 1991. Т. 37. № 3. C. 65-68.
  11. Кветной И.М., Райхлин Н.Т., Южаков В.В. и др. Экстрапинеальный мелатонин: место и роль в нейроэндокринной регуляции гомеостаза // Бюл. эксперим. биол. и мед. 1999. Т. 127. № 4. C. 365-370.
  12. Hardeland R., Pandi-Perumal S.R., Cardinali D.P. Melatonin // Int. J. Biochem. Cell. Biol. 2006. V. 38. № 3. P. 313-316.
  13. Finocchiaro L.M., Nahmod V.E., Launay J.M. Melatonin biosynthesis and metabolism in peripheral blood mononuclear leucocytes // Biochem. J. 1991. V. 280. № 3. P. 727-731.
  14. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists // Neuropsychiatr. Dis. Treat. 2009. № 5. P. 341-354.
  15. Brown G.M., Pandi-Perumal S.R., Trakht I. et al. Melatonin and its relevance to jet lag // Travel Med. Infect. Dis. 2009. V. 7. № 2. P. 69-81.
  16. Escames G., Acuna-Castroviejo D. Melatonin, synthetic analogs, and the sleep/wake rhythm // Rev. Neurol. 2009. V. 48. № 5. P. 245-254.
  17. Srinivasan V., Pandi-Perumal S.R., Trakht I. et al. Pathophysiology of depression: role of sleep and the melatonergic system // Psychiatry Res. 2009. V. 165. № 3. P. 201-214.
  18. Maldonado M.D., Perez-San-Gregorio M.A., Reiter R.J. The role of melatonin in the immuno-neuro-psychology of mental disorders // Recent. Pat. CNS Drug. Discov. 2009. V. 4. № 1. P. 61-69.
  19. Арушанян Э.Б., Арушанян Л.Г. Эпифизарный мелатонин как антистрессорный агент // Эксперим. и клинич. фармакол. 1997. Т. 60. № 6. С. 71-77.
  20. Konakchieva R., Mitev Y., Almeida O.F. et al. Chronic melatonin treatment and the hypothalamo-pituitary-adrenal axis in the rat: attenuation of the secretory response to stress and effects on hypothalamic neuropeptide content and release // Biol. Cell. 1997. V. 89. № 9. P. 587-596.
  21. Reiter R.J., Tan D.X., Manchester L.C. et al. Melatonin and reproduction revisited // Biol. Reprod. 2009. V. 81. № 3. P. 445-456.
  22. Reiter R.J., Tan D.X., Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact on hypertension // J. Hypertens. 2009. V. 6. P. 17-20.
  23. Cardinali D.P., Esquifino A.I., Srinivasan V. et al. Melatonin and the immune system in aging // Neuroimmunomodulation. 2008. V. 15. № 4-6. P. 272-278.
  24. Srinivasan V., Spence D.W., Trakht I. et al. Immunomodulation by melatonin: its significance for seasonally occurring diseases // Neuroimmunomodulation. 2008. V. 15. № 2. P. 93-101.
  25. Srinivasan V., Spence D.W., Pandi-Perumal S.R. et al. Therapeutic actions of melatonin in cancer: possible mechanisms // Integr. Cancer Ther. 2008. V. 7. № 3. P. 189-203.
  26. Korkmaz A., Topal T., Tan D.X. et al. Role of melatonin in metabolic regulation // Rev. Endocr. Metab. Disord. 2009. V. 10. № 4. P. 261-270.
  27. Hardeland R. Melatonin: signaling mechanisms of a pleiotropic agent // Biofactors. 2009. V. 35. № 2. P. 183-192.
  28. Jockers R., Maurice P., Boutin J.A. et al. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new - // Br. J. Pharmacol. 2008. V. 154. № 6. P. 1182-1195.
  29. Gall C., Stehle J.H., Weaver D.R. Mammalian melatonin receptors: molecular biology and signal transduction // Cell. Tissue. Res. 2002. V. 309. P. 151-162.
  30. Dubocovich M.L., Riviera-Bermudez M.A., Gerdin M.J. et al. Pharmacology, regulation and function of mammalian melatonin receptors // Front. Biosci. 2003. № 8. P. 1093-1098.
  31. Nosjean O., Nicolas J. P., Klupsch F. et al. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2 // Biochem. Pharmacol. 2001. V. 61. P. 1369-1379.
  32. Carlberg C. Gene regulation by melatonin // Ann. N. Y. Acad. Sci. 2000. V. 917. P. 387-396.
  33. Dubocovich M.L., Markowska M. Functional MT1 and MT2 melatonin receptors in mammals // Endocrine. 2005. V. 27. P. 101-110.
  34. Sethi S., Adams W., Pollock J. et al. C-terminal domains within human MT1 and MT2 melatonin receptors are involved in internalization processes // J. Pineal Res. 2008. V. 45. P. 212-218.
  35. Kato K., Hirai K., Nishiyama K. et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist // Neuropharmacol. 2005. V. 48. P. 301-310.
  36. McNulty S., Ross A.W., Shiu K.Y. et al. Phosphorylation of CREB in ovine pars tuberalis is regulated both by cyclic AMP-dependent and cyclic AMP-independent mechanisms // J. Neuroendocrinol. 1996. № 8. P. 635-645.
  37. Chan A.S., Lai F.P., Lo R.K. et al. Melatonin MT1 and MT2 receptors stimulate C-Jun N-terminal kinase via pertussis toxinsensitive and -insensitive G proteins // Cell. Signal. 2002. V. 14. P. 249-257.
  38. Pandi-Perumal S.R., Trakht I., Srinivasan V. et al. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways // Prog. Neurobiol. 2008. V. 85. P. 335-353.
  39. Petit L., Lacroix I., Coppet P. et al. Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3′-5′-monophosphate pathway // Biochem. Pharmacol. 1999. V. 58. P. 633-639.
  40. Nelson C.S., Marino J.L., Allen C.N. Melatonin receptor activate heterotrimeric G-protein coupled Kir3 channels // Neuroreport. 1996. № 7. P. 717-720.
  41. Geary G.G., Krause D.N., Duckles S.P. Melatonin directly constricts rat cerebral arteries through modulation of potassium channels // Am. J. Physiol. 1997. V. 273. P. 1530-1536.
  42. Ayoub M.A., Levoye A., Delagrange P. et al. Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers // Mol. Pharmacol. 2004. V. 66. P. 312-321.
  43. Kokkola T., Vaittinen M., Laitinen J.T. Inverse agonist exposure enhances ligand binding and G protein activation of the human MT1 melatonin receptor, but leads to receptor down-regulation // J. Pineal Res. 2007. V. 43. № 3. P. 255-262.
  44. Bondi C.D., McKeon R.M., Bennett J.M. et al. MT1 melatonin receptor internalization underlies melatonin-induced morphologic changes in Chinese hamster ovary cells and these processes are dependent on Gi proteins, MEK 1/2 and microtubule modulation // J. Pineal Res. 2008. V. 44. № 3. P. 288-298.
  45. Luttrell L.M., Lefkowitz R.J. The role of ß-arrestins in the termination and transduction of G-protein-coupled receptor signals // J. Cell. Sci. 2002. V. 115. P. 455-465.
  46. Gerdin M.J., Masana M.I., Rivera-Bermuґdez M.A. et al. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin // FASEB J. 2004. V. 18. P. 1646-1656.
  47. Reppert S.M., Weaver D.R., Ebisawa T. et al. Cloning of a melatonin-related receptor from human pituitary // FEBS Lett. 1996. V. 386. P. 219-224.
  48. Levoye A., Dam J., Ayoub M.A. et al. The orphan GPR50 receptor specifically inhibits MT(1) melatonin receptor function through heterodimerization // EMBO J. 2006. V. 25. P. 3012-3023.
  49. Mailliet F., Ferry G., Vella F. et al. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme // Biochem. Pharmacol. 2005. V. 71. P. 74-88.
  50. Tan D.X., Manchester L.C., Terron M.P. et al. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance // J. Pineal Res. 2007. V. 43. № 4. P. 317-320.
  51. Calamini B., Santarsiero B.D., Boutini J.A. et al. Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2 // Biochem. J. 2008. V. 413. P. 81-91.
  52. Boutin J.A., Marcheteau E., Hennig P. et al. MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate // J. Pineal Res. 2008. V. 45. № 4. P. 524-531.
  53. Giguere V., Tini M., Flock G. et al. Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR, a novel family of orphan hormone nuclear receptors // Genes & Dev. 1994. V. 8. P. 538-553.
  54. Maestroni G.J.M. The immunoneuroendocrine role of melatonin // J. Pineal Res. 1993. V. 14. P. 1-10.
  55. Steinhilberg D., Brungs M., Werz O. et al. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes // J. Biol. Chem. 1995. V. 270. P. 7037-7040.
  56. Rivara S., Mor M., Bedini A. et al. Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders // Curr. Top. Med. Chem. 2008. V. 8. № 11. P. 954-968.
  57. Zlotos D.P. Recent advances in melatonin receptor ligands // Arch. Pharm. Chem. Life Sci. 2005. V. 338. № 5-6. P. 229-247.
  58. Flaugh M.E., Bruns R.F., Clarke D.O. et al. Preliminary clinical studies on the melatonin agonist LY156735 / Gordon Research Conference on Pineal Cell Biology, 2000, Oxford, UK. P. 73-81.
  59. Millan M.J., Gobert A., Lejeune F. et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways // J. Pharmacol. Exp. Ther. 2003. V. 306. P. 954-964.
  60. Nonno R., Lucini V., Spadoni G. et al. A new melatonin receptor ligand with mt1-agonist and MT2-antagonist properties // J. Pineal Res. 2000. V. 29. № 4. P. 234-240.
  61. Audinot V., Mailliet F., Lahaye-Brasseur C. et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors // Naunyn-Schmiedeberg's Arch. Pharmacol. 2003. V. 367. P. 553-561.
  62. Descamps-Francois C., Yous S., Chavatte P. et al. Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands // J. Med. Chem. 2003. V. 46. № 7. P. 1127-1129.
  63. Epperson J.R., Deskus J.A., Gentile A.J. et al. 4-Substituted anilides as selective melatonin MT2 receptor agonists // Bioorg. Med. Chem. Lett. 2004. V. 14. № 4. P. 1023-1026.
  64. Faust R., Garratt P.J., Jones R. et al. Melatonin Agonists and Antagonists derived from 6H-Isoindolo[2.1-a]indoles, 5,6-Dihydroindolo[2,1-a]isoquinolines and 6,7-Dihydro-5H-benzo[3,4]azepino-[1,2-a]indoles //  J. Med. Chem. 2000. V. 43. P. 1050-1061.
  65. Molinari E.J., North P.C., Dubocovich M.L. 2-[125I]iodo-5-methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites // Eur. J. Pharmacol. 1996. V. 301. № 1-3. P. 159-168.
  66. Wiesenberg I., Missbach M., Kahlen J. P. et al. Transcriptional activation of the nuclear receptor RZR alpha by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand // Nucleic Acids Res. 1995. V. 23. № 3. P. 327-333.
  67. Witt-Enderby P.A., Li P.K. Melatonin receptors and ligands. Vitam. Horm. 2000. V. 58. P. 321-354.
  68. Steinhilberg D., Carlberg C. Melatonin receptor ligands // Exp. Opin. Ther. Patents. 1999. № 9. P. 281-290.
  69. Depreux P., Lesieur D., Mansour H.A. et al. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands // Med. Chem. 1994. V. 37. P. 3231-3239.
  70. Tarzia G., Diamantini G., Giacomo B. et al. 1-(2-Alkanamidoethyl)-6-methoxyindole derivatives: a new class of potent indole melatonin analogues // J. Med. Chem. 1997. V. 40. P. 2003-2010.
  71. Yous S., Andrieux J., Howell H.E. et al. Novel naphthalenic ligands with high affinity for the melatonin receptors // J. Med. Chem. 1992. V. 35. P. 1484-1486.
  72. Giacomo B., Bedini A., Spadoni G. et al. Synthesis and biological activity of new melatonin dimeric derivatives // Bioorg. Med. Chem. 2007. V. 15. P. 4643-4650.
  73. Missbach M., Jagher B., Sigg I. et al. Thiazolidine diones, specific ligands of the nuclear receptor retinoid Z receptor/retinoid acid receptor-related orphan receptor alpha with potent antiarthritic activity // J. Biol. Chem. 1996. V. 271. № 23. P. 13515-13522.
  74. Arendt J. Melatonin and its agonists: an update // Br. J. Psychiatry 2008. V. 193. P. 267-269.
  75. Doghramji K. Melatonin and its receptors: a new class of sleep-promoting age // J. Clin. Sleep. Med. 2007. V. 3. № 5. P. 17-23.
  76. Bourin M., Mocaer E., Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors // J. Psychiatry Neurosci. 2004. V. 29. P. 126-133.
  77. Naguib M., Baker M.T., Spadoni G. et al. The hypnotic and analgesic effects of 2-bromomelatonin // Anesth. Analg. 2003. V. 97. № 3. P. 763-768.
  78. Karim A., Tolbert D., Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high affinity MT1 and MT2 melatonin receptor agonist indicated for the treatment of insomnia // J. Clin. Pharmacol. 2006. V. 46. P. 140-148.